These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11790296)

  • 1. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopeptidase inhibition for blood pressure control: emerging experience.
    Quaschning T
    Curr Pharm Des; 2005; 11(25):3293-9. PubMed ID: 16250856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition and endothelial function in hypertension.
    d'Uscio LV; Lüscher TF
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
    Machowska A; Juszczak K; Novak P; Thor P
    Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
    Kubota E; Dean RG; Hubner RA; Balding LC; Johnston CI; Burrell LM
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S31-3. PubMed ID: 11716804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibition: a double-edged sword?
    Campbell DJ
    Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.
    Tabrizchi R
    Drugs; 2003; 63(20):2185-202. PubMed ID: 14498755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopeptidase inhibitors.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
    Ferro CJ; Spratt JC; Haynes WG; Webb DJ
    Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q; Touyz RM; Schiffrin EL
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.